文章摘要

参考文献/References

［1］ Wolff AA, Rotmensch HH, Stanley WC, et al. Metabolic approaches to the treatment of ischemic heart disease: the clinicians' perspective［J］. Heart Fail Rev，2002 ，7(2):187-203.

［2］ Pauly DF, Pepine CJ. Ischemic heart disease: Metabolic approaches to management［J］. Clin Cardiol，2004，27(8):439-441 .

［3］ Lopaschuk GD. Targets for modulation of fatty acid oxidation in the heart［J］. Curr Opin Investig Drugs, 2004,5(3):290-294.

［4］ Sole MJ, Jeejeebhoy KN. Conditioned nutritional requirements: Therapeutic relevance to heart failure［J］. Herz，2002，27(2):174-178.

［5］ Jackson G .Clinical significance of metabolic approach to coronary heart disease［J］. Eur Heart J,1999,20(suppl 1):29.

［6］ Dyck JR,Cheng JF,Stanley WC, et al. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation［J］. Circ Res,2004, 94(9):e78-e84.

［7］ Apstein CS. Increased glycolytic substrate protection improves ischemic cardiac dysfunction and reduces injury［J］. Am Heart J, 2000, 139(2 pt 3): S107-S110.

［8］ Fontbonne A, Charles MA, Thibult N,et al. Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the paris prospective study 15yearfollowup［J］. Diabetologia, 1991, 34(2):356-365.

［9］ King GL,Goodman AD,Buzney S,et al.Receptor and growthpromoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta［J］. J Clin Invest,1985,75(3):1028-1035.

［10］FathOrdoubadi F,Beatt KJ.Glucoseinsulinpotassium therapy for treatment of acute myocardial infarction:An overview of randomized placedbocontrolled trials［J］. Circulation,1997,96(4):1152-1156.

［11］Diaz R,Paolasso EA,PiegasL S,et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group［J］. Circulation,1998,98(21):2227-2234.

［12］Lazar HL,Chipkin S,Philippides G, et al.Glucoseinsulinpotassium solutions improve outcomes in diabetics who have coronary artery operations［J］. Ann Thorac Surg,2000,70(1):145-150.

［13］Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of longchain 3ketoacyl coenzyme a thiolase［J］. Circ Res, 2003,93(3):e33-e37.

［14］Macinnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial longchain 3ketoacyl coenzyme a thiolase［J］. Circ Res,2003,93(3):e26-e32.

［15］Grynberg A. Effectors of fatty acid oxidation reduction: promising new antiischaemic agents［J］ . Curr Pharm Des,2005,11(4):489-509.

［16］Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine［J］. Fundam Clin Pharmacol,2003, 17(2):133-145.

［17］Steg PG,Grollier G,Gallay P,et al. A randomized double blind trial of intravenous trimelazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction［J］. Int J Cardiol, 2001,77(23):263-273.

［18］Lango R, Smolenski RT, Narkiewicz M,et al. Influence of Lcarnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass［J］ . Cardiovasc Res, 2001,51(1):21-29.

我们的网站为什么显示成这样？

心肌缺血的能量代谢障碍治疗进展(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

文章信息/Info

参考文献/References

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics